Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
US-10286065-B2 · May 14, 2019 · US
Methods and compositions for adaptive immune modulation
US11826422B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11826422-B2 |
| Application number | US-201716348829-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 9, 2017 |
| Priority date | Nov 9, 2016 |
| Publication date | Nov 28, 2023 |
| Grant date | Nov 28, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Embodiments are directed to methods and compositions for modulating an immune response. In certain aspects the immune response is a type I hypersensitivity response. In particular aspects the subject has allergic asthma or allergic rhinitis. Using a conventional experimental asthma mouse model (BALB/c), the inventors demonstrate that aerosol administration of TLR agonists, in particular a combination of TLR2/6 and TLR9 agonist (e.g., TLR9 oligonucleotide agonist/PAM2CSK4) along with an antigen (e.g., ovalbumin (OVA)) suppresses the immune response as exemplified by the production of antigen-specific IgE and decreases the number of airway eosinophils in bronchoalveolar lavage fluid (BAL) in response to intraperitoneal (IP) immunization with an antigen mixed with alum.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for attenuating type I hypersensitivity in a subject, comprising administering an effective amount of at a composition comprising PAM2CSK4 and ODNM362 to a subject susceptible to allergen induced asthma. 2. The method of claim 1 , wherein the subject has been exposed to the allergen. 3. The method of claim 1 , wherein the molar ratio of PAM2CSK to ODNM362 is 4:1. 4. The method of claim 1 , wherein the subject has allergic asthma. 5. A method for attenuating type I hypersensitivity in a subject, comprising administering an effective amount of a composition comprising TLR agonists and an allergen to a subject susceptible to allergen induced asthma; wherein the TLR agonists consist of PAM2CSK4 and ODNM362. 6. A pharmaceutically acceptable composition comprising PAM2CSK4, ODNM362, and an asthma-inducing allergen. 7. The composition of claim 6 , wherein the composition further comprises an anti-inflammatory agent. 8. The composition of claim 7 , wherein the anti-inflammatory agent is budesonide. 9. The composition of claim 6 , wherein the composition is sterile and essentially free of pathogenic microbes.
Assignees
Inventors
Classifications
Interference-related aspects · CPC title
Circuits · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
from pollen · CPC title
to the airways · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11826422B2 cover?
- Embodiments are directed to methods and compositions for modulating an immune response. In certain aspects the immune response is a type I hypersensitivity response. In particular aspects the subject has allergic asthma or allergic rhinitis. Using a conventional experimental asthma mouse model (BALB/c), the inventors demonstrate that aerosol administration of TLR agonists, in particular a combi…
- Who is the assignee on this patent?
- Univ Texas, Pulmotect Inc, Texas A & M Univ Sys, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/7088. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).